BD Launches BD FACSymphony™ S6 High Parameter Cell Sorter to Enable Sorting of Rare Cell Types

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD FACSymphony™ S6 cell sorter, which will be on display at the 33rd Congress of the International Society for Advancement of Cytometry next week in Prague. The new platform leverages the high parameter capabilities of the BD FACSymphony cell analyzer, giving researchers the ability to sort cell populations to better understand cell phenotypes for immunology and multi-omics research.

The BD FACSymphony S6 instrument offers six-way sorting and supports analysis of up to 30 parameters. It includes a scalable architecture that could be upgradable to enable greater parameter analysis in the future. This advanced platform features an ultra-quiet electronics system adapted from the defense industry that improves detection sensitivity to enable the sorting of rare cell types. Configurable through the Special Order Research Products (SORP) program, researchers will have the flexibility to customize their systems with up to nine spatially separated lasers each with multiple power ratings to fully leverage the broad portfolio of BD Horizon Brilliant™ reagents.
 

"The new BD FACSymphony S6 system is the newest advance in our 40 year history of leadership and innovation in flow cytometry and demonstrates our ongoing commitment to helping researchers better understand and characterize the single cell," said John Ledek, worldwide president of Biosciences for BD. "The additional technological capabilities this system brings our customers, coupled with our unmatched global support and application services teams, will help facilitate the discovery of new biological insights, enabling researchers to push the envelope of scientific inquiry."

BD's diverse portfolio of instruments, reagents and services provide a comprehensive research solution to address the needs of immunologists and other researchers adopting flow cytometry to complement adjacent technologies and workflows. BD's portfolio of research analyzers and cell sorters, spanning from entry-level systems to this new advanced BD FACSymphony S6 cell sorter, exemplifies the company's commitment to democratizing flow cytometry across the spectrum of research applications.

Advertisement

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
BD reports revenues of $2.051 billion for second fiscal quarter 2015